- NASDAQ:JAGX surged by 49.25% on Friday to close a tremendous first week of 2021.
- JAGX will receive pre-clinical support from the National Institute of Allergy and Infectious Diseases.
- Jaguar Health is pushing its drug Lechlemer for wider use in patients.
NASDAQ:JAGX has had an eventful start to 2021 as the micro-cap biotech firm has already surged by over 266% in the first week of trading. While these gains are obviously magnified because of its penny stock status, the bull run from investors is pointing towards a very real positive trajectory for the rest of 2021. On Friday, Jaguar Health Inc gained another 49.25% to close the trading week at $4.00 per share as the stock hit an all new 52-week high of $4.47, before settling back down to the closing price.
There are several catalysts that have caused Jaguar Health’s breakout so far this year, not the least of which is newfound pre-clinical support from the National Institute of Allergy and Infectious Diseases. The government agency will be providing some brief clinical studies on how the drug Lechlemer affects dogs and rats. Lechlemer is Jaguar Health’s leading potential treatment for cholera-induced diarrhea and is a cheaper alternative to its current offering Crofelemer. Because of this difference in costs, Jaguar Health is hoping to receive a priority review from the FDA sometime this year.
JAGX stock forecast
Biotech stocks with low market caps are often the targets of investors who want large gains in a short amount of time. Jaguar Health certainly fits this bill and seems to be one of the flavours of the week so far in 2021. If Jaguar is able to fulfil any of its potential treatments in 2021, we could soon see the company shed its penny stock status for good.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD stuck around 1.0500 as investors await fresh catalysts
EUR/USD seesaws around the 1.0500 level, unable to find a clear directional path. EU PMI data came in better than expected but still indicate contraction in the Union. United States PMIs show a steeper contraction in the manufacturing sector yet upbeat services output in December.
Gold stuck around $2,650 ahead of fresh clues
Gold opens the week on a moderately positive tone and trades above $2,650, favored by a mild US Dollar (USD) reversal amid lower US Treasury yields. The precious metal, however, is still close to recent lows following a 2.5% sell-off late last week.
Crypto Today: MicroStrategy drives BTC to $107K as Fed cut hype sparks Ondo, Chainlink rallies
The global crypto market snapped out of a tepid start to the month after hotter-than-expected consumer inflation data sparked hopes of a third consecutive US Fed rate cut.
Five fundamentals for the week: Fed dominates the last full and busy trading week of the year Premium
Christmas is coming – but there's a high likelihood of wild price action before the holiday season begins. Central banks take center stage, and there is enough data to keep traders busy outside these critical decisions.
Five fundamentals for the week: Fed dominates the last full and busy trading week of the year Premium
Christmas is coming – but there's a high likelihood of wild price action before the holiday season begins. Central banks take center stage, and there is enough data to keep traders busy outside these critical decisions.
Best Forex Brokers with Low Spreads
VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.